Abstract:Introduction Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated. Methods The ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis. Results ERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells. Conclusions Although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process.

Estrogen Receptor Α-Mediated Signaling Inhibits Type I Interferon Response to Promote Breast Carcinogenesis

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Estrogen Receptor Alpha Inhibits RLR-mediated Immune Response Via Ubiquitinating TRAF3.

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

The expressing signification of estrogen receptorβ in breast cancer

ER is an RNA-binding protein sustaining tumor cell survival and drug resistance

Type I IFN stimulates IFI16-mediated aromatase expression in adipocytes that promotes E2-dependent growth of ER-positive breast cancer

Estrogen receptors participate in carcinogenesis signaling pathways by directly regulating NOD-like receptors.

Stable Knockdown of Estrogen Receptor Alpha by Vector-Based Rna Interference Suppresses Proliferation and Enhances Apoptosis in Breast Cancer Cells

Effects Of Estrogen On Breast Cancer Development: Role Of Estrogen Receptor Independent Mechanisms

Attenuation of Estrogen Receptor Alpha-Mediated Transcription Through Estrogen-Stimulated Recruitment of A Negative Elongation Factor

Autocrine Interferon-Γ May Affect Malignant Behavior and Sensitivity to Tamoxifen of MCF-7 Via Estrogen Receptor Β Subtype

Rnf168 Facilitates Oestrogen Receptor Alpha Transcription And Drives Breast Cancer Proliferation

Fulvestrant-Mediated Inhibition of Estrogen Receptor Signaling Slows Lung Cancer Progression

Over expression of estrogen receptor- related receptor α provide a potential resistant mechanism to endocrine therapy

Analysis of Clinico-Pathological Factors Which Influence the Expression of Estrogen Receptor in Breast Carcinoma

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes

ERα Inhibits Epithelial-Mesenchymal Transition by Suppressing Bmi1 in Breast Cancer.

[Molecular Mechanisms of Regulation of Estrogen Receptor a Expression Level in Breast Cancer].

A Role of Estrogen/erα Signaling in BRCA1-associated Tissue-Specific Tumor Formation